2158 related articles for article (PubMed ID: 24345736)
1. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.
Tian Y; Li S; Song J; Ji T; Zhu M; Anderson GJ; Wei J; Nie G
Biomaterials; 2014 Feb; 35(7):2383-90. PubMed ID: 24345736
[TBL] [Abstract][Full Text] [Related]
2. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
3. Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy.
Wang C; Li N; Li Y; Hou S; Zhang W; Meng Z; Wang S; Jia Q; Tan J; Wang R; Zhang R
J Nanobiotechnology; 2022 May; 20(1):247. PubMed ID: 35642064
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
5. Cucumber mosaic virus as drug delivery vehicle for doxorubicin.
Zeng Q; Wen H; Wen Q; Chen X; Wang Y; Xuan W; Liang J; Wan S
Biomaterials; 2013 Jun; 34(19):4632-42. PubMed ID: 23528229
[TBL] [Abstract][Full Text] [Related]
6. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.
Jang SC; Kim OY; Yoon CM; Choi DS; Roh TY; Park J; Nilsson J; Lötvall J; Kim YK; Gho YS
ACS Nano; 2013 Sep; 7(9):7698-710. PubMed ID: 24004438
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells.
Ke XY; Lin Ng VW; Gao SJ; Tong YW; Hedrick JL; Yang YY
Biomaterials; 2014 Jan; 35(3):1096-108. PubMed ID: 24183698
[TBL] [Abstract][Full Text] [Related]
8. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
9. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
10. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
11. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
12. iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma.
Liu Q; Dai G; Wu Y; Zhang M; Yang M; Wang X; Song M; Li X; Xia R; Wu Z
Front Oncol; 2022; 12():822805. PubMed ID: 35982974
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
15. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
16. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization.
Tinkov S; Coester C; Serba S; Geis NA; Katus HA; Winter G; Bekeredjian R
J Control Release; 2010 Dec; 148(3):368-72. PubMed ID: 20868711
[TBL] [Abstract][Full Text] [Related]
17. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy.
Cai D; Gao W; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2014 Feb; 35(7):2283-94. PubMed ID: 24360410
[TBL] [Abstract][Full Text] [Related]
18. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems.
Liu Y; Gao FP; Zhang D; Fan YS; Chen XG; Wang H
J Control Release; 2014 Jan; 173():140-7. PubMed ID: 24188958
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
20. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
